Obviously, LGA infants are maintaining high Aldo levels, whereas D O C levels were lower than in AGA.High fetal glucocorticoids (B, F,E) in LGA reflect either increased fetal stress andlor placental transfer of high maternal steroids. Additionally,elevated ylucocorticoids (B,F) from 12 h to 7 d point to a more stressful postnatal adaptation in LGA newborns. (CLAII) (20-27 DLISI.IOLASL oLrIc1mcY) CLAIi is a rare and often fatal disease due Lo d defect in the conversion of cholcstcrol to pregnenolone. We report on 4 individuals wit11 a fcnidlc phenotype, 3 of whom hdd a 46,XY karyotypc, while 1 had a 46,XX karyotype. All patients presented \riLI> signs of adrenal insufficiency during the first months of life, and one of them died 11 weeks of age. Of the surviving paticnts, 2 werc sisters, wlrile thcir parents as rvell as tire parents of Llrc fourth individual werc first cousins. These 3 ldtter paticnts have developed normally on glucocorticoid and mincralocorticoid rcplaccmcnt (observation time 14, 6, and 4 yedrs). The diagrrosis of tl~c surviving individuals sere bascd on extcnsivc hormonal dndlyses including urinary and serum levels of C19 and C21 steroids and their metabolites, serum levels of ACTII, plasma renin activity, and ACTH and hCG stimulation tests. The diaqnosis of the fatal casc was based on microscopy of thc ddrcnal gldnds shoning changes typical for CLAN. Thc results suggest 1) that a recessive mode of inhcritdncc might be involved, 2) that the patients may develop satisfactorily on glucocorticoid and minerdlocorticoid replacement, and confirm 3) that the disease may affect 46.XX individuals. The diagnosis of CAH and treatment response, based on plasma steroid measurements, was reviewed in 9 infants (5M, 4F) in relation to hydrocortisone (HC) dose and growth velocity in the first 3 years. Two siblings had 11p-OH deficiency; the remainder had salt-losing 2lOH deficiency. Mean pre-treatment 170H-progesterone (17P) and 11-deoxycortisol levels were 367 and 2000 nrnolll respectively in the relevant groups. Plasma 17P levels fluctuated widely during the day (31-4130 nmolll) with no diurnal pattern. Testosterone (T) levels (mean 13.2, range 1.5 -26 nmolll) were increased to adult male Levels but no male was virilized. Maintenance HC (mean 25.7 mg/ms/day) in 3 divided doses (and fludrocortisone 0.1-0.15 mglday) normalized 17P levels by 3 months (median 33, 75th centile 90 nmol/L); mean T levels fell to 1.1 nmol/L (range 0.4 -2.7) by 3 months in females, whereas similar levels in males were delayed until 6 months due to testicular T production. A mean HC dose falling to 15.3 mg/m2/day by 3 yr maintained normal 17P and T levels; growth velocity SDS was -0.91 i 1.3 (mean i SD) at 9 months and remained normal thereafter.
Maintenance HC doses at the onset of treatment in CAH results in satisfactory control by 3 months (including the T surge in male infants) and ensure a rapid growth velocity characteristic of early infancy. 16 patients with CAH were studied at home.Blood was collected fasting at bed rest between 7-8 AM and 3 hrs. after normal activity.Specimens were immediately centrifuged on ice and frozen.24-hour urine and 3-hourly saliva samples during daytime were obtained from 12 noon on the previous day.17-OH-progesterone (17-OHP) was measured in plasma and saliva;testosterone,aldosterone,renin activity (PRA) and AT I1 in plasma only and 17-ketosteroids,pregnanetriol (P'triol) and sodium in the urine. No values were normally distributed.Statistica1 evaluation used the Wilcoxon rank test and discriminant analysis. Results: highly significant correlations existed between plasma and saliva 17-OHP at 8 AM, PRA and AT I1 at 8 and 11 AM,and 8 AM 17-OHP and P'triol e.g. When patients were divided into well and poorly suppressed groups according to their 8 AM 17-OHP-and P'triol-values to find additional usetul monitoring parameters,saliva 17-OHP proved highly discriminating,while the probability of error was 18% for AT I1 and 26% for PHA.
Discriminant analysis showed correct classification c g . by saliva 17-OHP in 77%,but none by PRA or AT 11. Conclusion:AT I1 has no value in monitoring CAH-therapy
